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access routes were transfemoral (n=164), transapical (n=54), axillary (n=5), or
transaortic (n=4). A CoreValve prosthesis was implanted in 174 patients, and a Sapien
prosthesis in 53 patients. Clinical and echocardiographic investigation was performed
at 6 months, one and two years.
Results: Survival was 88.5% at 30 days, 75.9% at six months, 74.5% at 1 year, and
and 64.4% at 2 years. Patients improved significantly in NYHA class after 6 months
(from 3.2±0.5 to 1.7±0.7, p<0.001) and up to two years (1.9±0.7). Cumulate incidences
of myocardial infarction, stroke, life-threatening or major bleeding were 2.7%, 6.2%,
and 16.2% at two years. The postprocedural mean transprosthetic gradient was 12±4
mmHg for all valves and did not change up to 2 years, the effective orifice area was
1.5±0.4 cm2 without any change over 2 years of FU. Moderate or severe prosthetic
regurgitation was present in 8% of patients at two years. In 6% of patients, the
paravalvular or valvular regurgitation grade increased significantly over time.
Conclusion: With excellent functional recovery of the patients, good systolic valve
function, and overall low morbidity at two years, we conclude TAVI can be considered
the treatment of choice for aortic valve stenosis in the elderly patient with an increased
risk for surgery with heart-lung-machine.
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Background: Transcatheter aortic valve replacement (TAVR) may be considered for
those with severe aortic stenosis who are considered inoperable or at high risk for
surgical replacement. We report the 30 day outcomes of the Edwards Sapien Source
Registry in Australia and New Zealand
Methods: This study enrolled 133 subjects at eight centres since December 2008.
Inclusion criteria included severe symptomatic aortic valve disease, symptomatic
degenerative aortic stenosis (AVA ≤ 0.8cm2), logistic Euroscore > 20% or STS > 10%,
agreement between surgeon and cardiologist that the patient not suitable for open
surgery due to high risk.
Results: A total of 133 were enrolled with complete data for 99 patients consisting of
53 transfemoral (TF) and 46 transapical (TA) implants. The mean age 82.6 yr (TF) and
83.6 yr (TA), female 32.1% (TF) 56.5% (TA), logistic Euroscore 27.6% (TF) 30.7%
(TF) with procedural success (successful implant without conversion to surgery or
death) of 92.3% (TF) 87% (TA) (p=0.384). Thirty day outcomes were not significantly
different between TF and TA implants. These included mortality of 3.8% (TF) 8.7%
(TA) (p=0.38), Major Adverse Cardiac and Cerebrovascular Events 5.7% (TF) and
13.0% (TA) (p=0.205), pacemaker 2.2% (TF) 0% (TA) (p=0.283), and VARC major
vascular complication of 6.5% (TF) 5.7% (TA) (p=0.859).
Conclusion: TAVR with the Edwards Sapien device is safe and effective therapy by
TA or TF route. A high procedural success rate was achieved with an acceptable
incidence of adverse events for a patient group at high risk for open surgery.
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Background: Trancatheter aortic valve implantation (TAVI) has emerged as an
accepted treatment option for high risk patients with severe aortic stenosis. The study
was designed to evaluate the safety and efficacy of transapical aortic valve implantation
in high risk patients using a second generation TAVI device, the JenaValveTM aortic
valve replacement system. It consists of a biological porcine valve mounted on a self-
expanding Nitinol stent. Retrieval capability, feeler guided anatomically correct
positioning, and clipping fixation on the diseased leaflets provide potential advantages
compared to current TAVI systems.
Methods: This is a prospective, single arm study conducted at seven German sites
including up to 70 patients. Enrollment started in November 2010 and will be
completed in June 2011.The valve is implanted via apical approach without rapid
pacing under fluoroscopic control. Primary endpoint is all cause mortality at 30 days.
Secondary endpoints, procedural success, major adverse cerebrovascular and cardiac
events, functional improvement and echocardiographic valve performance will be
assessed at procedure, post-procedure, discharge, 30 day, 3, 6, and 12 months.
Results: Three months safety and effectiveness outcomes will be presented for high
risk patients undergoing transapical aortic valve implantation. For primary and
secondary categorical endpoints estimates of absolute frequencies relative to patients
at risk and their 95% two-sided confidence interval will be calculated. Changes to
baseline will be given for all variables recorded at different time points, and tests on
pre-post difference will be performed with methods suited to scale this data.
Conclusion: Transapical aortic valve implantation has shown to be an excellent
treatment option in high risk patients with symptomatic aortic stenosis. However,
reports on clinical outcomes using second generation devices are still limited. The
study results will provide important data about the safety and efficacy of this next
generation device.
TCT-789
Clinical Profile and Outcome Correlates in Patients with Severe Aortic Stenosis
at High Surgical Risk: Prospective Evaluation According to Treatment
Assignment
Danny Dvir, Alexander Sagie, Eyal Porat, Abid Assali, Yaron Shapira, Hana Vaknin-
Assa, Vachislav Bobovnikov, Gideon Shafir, Tamir Bental, Nurit Shor, Arnon Koren,
Leonid Eidelman, Alexander Battler, Ran Kornowski
Rabin Medical Center, Petah-Tikva, Israel
Background: Transcatheter aortic-valve implantation (TAVI) is a therapeutic
alternative to surgical aortic-valve replacement (SAVR) in high-risk patients with
severe aortic stenosis (AS). Patients ineligible for both SAVR and TAVI are treated
with medication, with or without balloon valvuloplasty (BV). There are very few data
on the outcome of these patients according to the treatment assigned in the current
TAVI era.
Methods: The study included 403 high-risk patients (55.8% female, age 81.4±7.1
years) with severe AS referred to a dedicated “TAVI clinic” with meticulous screening
and multidisciplinary team evaluation. Technical and procedural success (VARC
definitions) and outcome were assessed during median follow-up of 292 days (IQR
138-522).
Results: Of the 343 patients assigned treatment, 100 (29.2%) underwent TAVI (56
CoreValve, 44 Edwards-SAPIEN), 61 (17.8%) SAVR, and 27 (7.9%) BV; 155 patients
(45.2%) were given medication only. The BV group had more comorbidities than the
other groups, represented by a higher logistic EuroSCORE (30.2±21.6 vs. 22.9±14.3,
p<0.001) and STS score (14.1±6.7 vs. 10.8±5.3, p<0.001). One-month mortality rate
was higher in the BV group (18.5%) than in each of the other groups (TAVI 3%, SAVR
11.8%, medication 3.2%; p<0.001). At one-year, patients after TAVI and SAVR had
lower mean valve gradients (8+4.6mmHg and 13+5.2, respectively) than the BV group
(29.4±18.6) and the medication group (46.2±24.3) (p<0.001); rates of high functional
class (NYHA I/II) were as follows: TAVI, 91%; SAVR, 79%; BV, 38%; medication,
16% (p<0.001). One-year mortality rate was dramatically lower in the TAVI group
(8.5%) than in the other groups (SAVR 29.8%, BV 39.6%, medication 38.7%; p<
0.001). Multivariable adjustment analysis identified renal failure (GFR<60cc/min, HR:
4.5, p<0.001) and pulmonary pressure (1mmHg, HR: 1.02, p=0.002) as independent
correlates for 1-year mortality in the total group; STS score (1%, HR: 1.1, p=0.001) in
the AVR group and peripheral vascular disease and in the BV group (HR 6.9, p=0.015).
Conclusion: This prospective clinical evaluation suggests that among the treatment
options for high-risk patients with severe AS, TAVI is associated with an excellent
prognosis in carefully selected patients. Patients excluded from TAVI had worse
outcomes, regardless of the elected mode of treatment, including SAVR.
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Background: Transcatheter aortic valve replacement (TAVI) has become an alternative
therapy in patients with high surgical risk. Among the major drawbacks of this
procedure is the potential need for postprocedural permanent pacemaker implantation
(PPM) due to bradyarrhythmias.
Methods: We performed a retrospective single center analysis in 130 consecutive
patients with successful transfemoral Corevalve implantation without preexisting PPM
implants and analyzed postinterventional bradyarrhythmias.
Results: Postprocedural bradyarrhythmias occurred in 47 patients (36.2%) post-TAVI.
PPM was performed in 46 patients. One patient died due to asystole. Compared to
those without postinterventional bradyarrhythmias, these patients had longer
preprocedural PR-intervals (P=0.012), broader QRS-complexes (P=0.001) and
prolonged QTc-intervals (P=0.001). Moreover, patients with postinterventional
bradyarrhythmias had more often preprocedural RBBB (P=0.0059) and a strong trend
towards increased numbers of preprocedural AVB grade I (P=0.0637). No difference
was observed with respect to annulus/prosthesis ratio (P = 0.377) or the use of a large
prosthesis (P = 0.2320). The vast majority developed bradyarrhythmias directly after
CoreValve implantation or within the first 48 hours (37 out of 47 patients). However,
the remaining 10 patients developed significant bradyarrhythmia more than 72 hours
after TAVI, when the provisional pacemaker had already been removed, and among
them were 5 patients (3.8% of the whole cohort), who developed them very late after
TAVI (240±129 h post TAVI), of which 1 died from asystole at day 5 post TAVI. The
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